Kyverna Therapeutics Inc (KYTX) Stock Price, Quote & News

Company Profile

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product cand...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 925 2492

Website: kyvernatx.com

Address:

5980 Horton Street, Suite 550, EmeryVille, United States

hbkstockislife Sep. 16 at 8:44 PM

$KYTX another 6.90$ to go for this scam .Will be 0 soon

0 · Reply

HarryScrotmmm Sep. 16 at 7:35 PM

$KYTX added at $6.92 and still have an open limit at $6.88.

0 · Reply

mike755 Sep. 16 at 7:33 PM

$KYTX is being dragged down by the market. KYTX is screamingly cheap compared to fundamentals. Buy and hold for a few years.

0 · Reply

Mden Sep. 15 at 9:21 PM

$KYTX anything new from the recent two conferences?

4 · Reply

mike755 Sep. 15 at 8:19 PM

$KYTX RSI is 34.78. KYTX hasn’t been so oversold for the last year.

0 · Reply

HarryScrotmmm Sep. 15 at 8:00 PM

$KYTX i just added a tiny bit at 6.95. I don't like the action at all. I thought the chat yesterday was goid. Who knows

1 · Reply

Jellysquid1 Sep. 15 at 7:52 PM

$KYTX Approval Will Come!

0 · Reply

xersdave Sep. 15 at 6:55 PM

$KYTX Can we fast forward to approval please?

1 · Reply

ZackInvest008 Sep. 15 at 4:05 PM

$KYTX

0 · Reply

Belisimo Sep. 15 at 4:04 PM

$KYTX Everything is positive out of his mouth. I'm not sure why he decided to do these interviews prior to the data coming out this month? Last week he said in a couple of weeks and now he said in a couple of weeks but in his last comments in a few weeks? For the updates

1 · Reply

Kyverna Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Sep 14, 2026, 4:05 PM EDT - 2 days ago

Kyverna Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

Sep 9, 2026, 4:30 PM EDT - 7 days ago

Kyverna Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference

Sep 2, 2026, 4:05 PM EDT - 14 days ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences

2026-08-11T20:15:41.000Z - 5 weeks ago

Kyverna Therapeutics reports Q2 EPS (63c), consensus (68c)

Aug 11, 2026, 4:02 PM EDT - 5 weeks ago

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

Aug 11, 2026, 4:00 PM EDT - 5 weeks ago

Kyverna Therapeutics Earnings release: Q2 2026

Aug 11, 2026, 4:00 PM EDT - 5 weeks ago

Kyverna Therapeutics Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 5 weeks ago

Kyverna Therapeutics Slides: Corporate presentation

2026-07-27T12:11:33.000Z - 7 weeks ago

Kyverna Therapeutics, ElevateBio announce miv-cel manufacturing agreement

Jul 27, 2026, 8:00 AM EDT - 7 weeks ago

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel

2026-06-22T12:11:14.000Z - 2 months ago

Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Jun 3, 2026, 3:10 PM EDT - 3 months ago

Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

2026-06-03T13:00:42.000Z - 3 months ago

Kyverna Therapeutics presents updated COMPARE trial data at EULAR

$Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis$

Jun 3, 2026, 8:00 AM EDT - 3 months ago

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Jun 3, 2026, 7:00 AM EDT - 3 months ago

Kyverna Therapeutics Slides: Corporate presentation

May 27, 2026, 2:00 PM EDT - 3 months ago

Kyverna Therapeutics Transcript: AGM 2026

May 19, 2026, 2:30 PM EDT - 4 months ago

Kyverna Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

2026-05-18T12:16:11.000Z - 4 months ago

Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed

IRWD

May 18, 2026, 8:00 AM EDT - 4 months ago

Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

2026-05-15T10:20:21.000Z - 4 months ago

Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright

2026-05-13T11:20:39.000Z - 4 months ago

Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan

2026-05-12T22:38:44.000Z - 4 months ago

Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)

May 12, 2026, 4:02 PM EDT - 4 months ago

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

May 12, 2026, 4:00 PM EDT - 4 months ago

Kyverna Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 4 months ago

Kyverna Therapeutics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 4 months ago

Kyverna Therapeutics Slides: Investor presentation

2026-05-04T12:45:05.000Z - 4 months ago

Kyverna Therapeutics appoints Nadia Dac as chief commercial officer

OMER

May 4, 2026, 8:00 AM EDT - 4 months ago

Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

Apr 22, 2026, 7:00 AM EDT - 4 months ago

Kyverna Therapeutics Transcript: Status update

Apr 22, 2026, 7:00 AM EDT - 4 months ago

Kyverna Therapeutics Press release: Status update

Apr 22, 2026, 7:00 AM EDT - 4 months ago

Kyverna Therapeutics Slides: Status update

2026-04-21T22:50:16.000Z - 4 months ago

Kyverna Therapeutics reports ‘positive’ results from KYSA-8 trial of miv-cel

Apr 21, 2026, 6:45 PM EDT - 4 months ago

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

2026-04-20T13:12:24.000Z - 4 months ago

Kyverna Therapeutics presents longer-term Phase 2 data for Miv-cel

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

Apr 13, 2026, 8:00 AM EDT - 5 months ago

Kyverna Therapeutics Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 5 months ago

Kyverna Therapeutics Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 5 months ago

Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

2026-03-26T20:25:22.000Z - 5 months ago

Kyverna Therapeutics files $300M mixed securities shelf

2026-03-26T20:12:42.000Z - 5 months ago

Kyverna Therapeutics reports Q4 EPS (80c), consensus (86c)

Mar 26, 2026, 4:02 PM EDT - 5 months ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 26, 2026, 4:00 PM EDT - 5 months ago

Kyverna Therapeutics Annual report: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 5 months ago

Kyverna Therapeutics Earnings release: Q4 2025

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Kyverna Therapeutics Registration statement: Registration filing

Mar 26, 2026, 7:00 AM EDT - 5 months ago

Kyverna Therapeutics Slides: Corporate presentation

Mar 9, 2026, 11:20 AM EDT - 6 months ago

Kyverna Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 4:21 PM EST - 6 months ago

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Mar 3, 2026, 8:00 AM EST - 6 months ago

Kyverna Therapeutics to Participate in Upcoming March Investor Conferences

2026-02-24T13:20:34.000Z - 6 months ago

Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board

BEAM

Feb 24, 2026, 8:00 AM EST - 6 months ago

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

2026-02-03T13:25:38.000Z - 7 months ago

Kyverna Therapeutics appoints Pujols as Chief Technology Officer

Feb 3, 2026, 8:00 AM EST - 7 months ago

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

Jan 14, 2026, 12:45 PM EST - 8 months ago

Kyverna Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:45 PM EST - 8 months ago

Kyverna Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T13:38:56.000Z - 8 months ago

Kyverna Therapeutics provides corporate update, priorities for 2026

Jan 12, 2026, 8:00 AM EST - 8 months ago

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 8 months ago

Kyverna Therapeutics Slides: Investor presentation

Jan 5, 2026, 8:00 AM EST - 8 months ago

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 17, 2025, 9:24 AM EST - 9 months ago

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 9 months ago

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 8:00 AM EST - 9 months ago

Kyverna Therapeutics Transcript: Study Result

Dec 15, 2025, 8:00 AM EST - 9 months ago

Kyverna Therapeutics Press release: Study Result

Dec 15, 2025, 8:00 AM EST - 9 months ago

Kyverna Therapeutics Slides: Study Result

Dec 15, 2025, 6:42 AM EST - 9 months ago

Kyverna's cell therapy meets main goal of mid-stage study

Dec 15, 2025, 6:30 AM EST - 9 months ago

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Dec 14, 2025, 2:30 PM EST - 9 months ago

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Nov 17, 2025, 8:00 AM EST - 10 months ago

Kyverna Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:05 PM EST - 10 months ago

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:00 AM EST - 10 months ago

Kyverna Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Kyverna Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 10 months ago

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 3, 2025, 8:00 AM EST - 10 months ago

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Kyverna Therapeutics Transcript: Study Update

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Kyverna Therapeutics Press release: Study Update

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Kyverna Therapeutics Slides: Study Update

Oct 29, 2025, 6:30 AM EDT - 10 months ago

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Oct 25, 2025, 11:00 AM EDT - 10 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Sep 24, 2025, 9:05 AM EDT - 11 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Sep 15, 2025, 1:02 PM EDT - 1 year ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Sep 9, 2025, 11:00 AM EDT - 1 year ago

Kyverna Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 4:05 PM EDT - 1 year ago

Kyverna Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 11:00 AM EDT - 1 year ago

Kyverna Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 28, 2025, 11:00 AM EDT - 1 year ago

Kyverna Therapeutics Transcript: KOL Event

Aug 28, 2025, 11:00 AM EDT - 1 year ago

Kyverna Therapeutics Press release: KOL Event

Aug 28, 2025, 11:00 AM EDT - 1 year ago

Kyverna Therapeutics Slides: KOL Event

Aug 28, 2025, 8:00 AM EDT - 1 year ago

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Aug 25, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Aug 12, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Earnings release: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

Jun 4, 2025, 4:55 PM EDT - 1 year ago

Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 13, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 12, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Earnings release: Q1 2025

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Kyverna Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Kyverna Therapeutics Proxy statement: Proxy Filing

Mar 27, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Kyverna Therapeutics Registration statement: Registration Filing

Mar 10, 2025, 3:00 PM EDT - 1 year ago

Kyverna Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 3, 2025, 4:05 PM EST - 1 year ago

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 7, 2025, 11:42 AM EST - 1 year ago

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

hbkstockislife Sep. 16 at 8:44 PM

$KYTX another 6.90$ to go for this scam .Will be 0 soon

0 · Reply

HarryScrotmmm Sep. 16 at 7:35 PM

$KYTX added at $6.92 and still have an open limit at $6.88.

0 · Reply

mike755 Sep. 16 at 7:33 PM

$KYTX is being dragged down by the market. KYTX is screamingly cheap compared to fundamentals. Buy and hold for a few years.

0 · Reply

Mden Sep. 15 at 9:21 PM

$KYTX anything new from the recent two conferences?

4 · Reply

mike755 Sep. 15 at 8:19 PM

$KYTX RSI is 34.78. KYTX hasn’t been so oversold for the last year.

0 · Reply

HarryScrotmmm Sep. 15 at 8:00 PM

$KYTX i just added a tiny bit at 6.95. I don't like the action at all. I thought the chat yesterday was goid. Who knows

1 · Reply

Jellysquid1 Sep. 15 at 7:52 PM

$KYTX Approval Will Come!

0 · Reply

xersdave Sep. 15 at 6:55 PM

$KYTX Can we fast forward to approval please?

1 · Reply

ZackInvest008 Sep. 15 at 4:05 PM

$KYTX

0 · Reply

Belisimo Sep. 15 at 4:04 PM

1 · Reply

kenny91655 Sep. 15 at 3:27 PM

$KYTX Complete BLA submitted in the next 15 days. I would think we see a jump.

3 · Reply

kenny91655 Sep. 15 at 2:13 PM

$KYTX This is the buy zone

0 · Reply

Madmortigan Sep. 15 at 1:47 PM

$KYTX This is not looking good 😬

1 · Reply

mike755 Sep. 14 at 8:29 PM

$KYTX has a potential competitor in gMG. descartes-08 Will submit BLA in mid 2027. KYTX will complete enrollment by mid 2027. So probably one year lag. descartes-08 Has less side effects, but it needs 6 weekly infusions. It is less effective with MG-ADL score of -4.8 vs mic-cel -8.5. With QMG score at -6.0 vs -11.3 for mimic-cel. Standard of care was continued for Descartes-8 while standard of care was stopped for miv-cel.

2 · Reply

ValueBioTracker Sep. 14 at 5:36 PM

$KYTX The market is wrong here. Extremely undervalued. There is no competition in SPS, and the gMG data is the best compared to the SOC and any late-stage competitor. Plus, the durability data of the three early german patients, with 19+ months follow-up, is INCREDIBLE. Safety is very good as well. SPS + gMG has a clear +$1B potential in revenue, and the CEO just recently hinted that data in progressive MS is very good as well.

3 · Reply

Power2k Sep. 13 at 2:32 PM

$KYTX Adding more this week. https://x.com/FWCStocks/status/2099030260742283596

3 · Reply

Ritschier Sep. 12 at 8:34 PM

$KYTX Not that it matters much, and I'll admit to gossiping here, but why are you so ~sure? If it were my doc working on a seemingly successful breakthrough therapy, and my doc I'd donated $2M to to help the science move faster, I'd ask my doc to get me in. Sure, it'd take a lot of discretion to get through the treatment without much of a fuss, but she could have had access alongside the trial. Yeah, sorry, gossiping, but it makes me happy seeing her on stage again; though I'm not a fan, it's just such an inspiring thing to see.

1 · Reply

dcrown Sep. 12 at 2:47 PM

$KYTX @petermaskMD @strat @mulc @mike755 @bioland @ hummer2277 @th3m4askedst0nker @ccledez “We’ve been guiding to a pricing for miv-cel that would be a significant premium to current CAR T pricing” Industry analysts estimate that a premium-priced autoimmune CAR T therapy like miv-cel will likely target a one-time wholesale cost between $700,000 and $1.2 million

2 · Reply

lovestockstwits Sep. 11 at 11:05 PM

$KYTX why does this stock even exist ..Literally scam and one of the worst performing stocks in recent times

1 · Reply

hbkstockislife Sep. 11 at 10:27 PM

$KYTX can someone poke those mofo management and let them know we have two data this month

1 · Reply

hbkstockislife Sep. 11 at 10:23 PM

$KYTX last time this bitch was green ..can’t recall

1 · Reply

dcrown Sep. 11 at 9:53 PM

$KYTX @petermask @strat @mulc @mike755 @bioland @hummer2277 @th3m4askedst0nker @ccledez Current lol enjoy your weekend https://www.investing.com/news/transcripts/kyverna-at-wells-fargo-healthcare-conference-autoimmune-car-t-push-advances-93CH-4894675

0 · Reply

Market Cap	457.64M
Revenue (ttm)	0.00
Net Income (ttm)	-161.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.15

Volume	685,583
Avg Vol	873,342
Day's Range	N/A - N/A
Shares Out	61.84M
Stochastic %K	5%
Beta	1.98
Analysts	Strong Sell
Price Target	$30.40